Purpose: The AACR Career Development Awards in Cancer Research will be presented for the first time in 1999. These two-year, international awards support research by junior, tenure-track scientists, at the level of Assistant Professor, who are engaged in meritorious cancer research at an academic institution anywhere in the world. The AACR-National Foundation for Cancer Research Career Development Award is restricted to proposals in basic research related to any type of cancer. The AACR-Susan G. Komen Breast Cancer Foundation Career Development Award is restricted to proposals for basic, clinical, or translational research related to breast cancer, including epidemiological and prevention studies.

Support: The two-year, international grants provide $50,000 per year. The grant covers direct research expenses, which may include payments to research assistants. The grant is not intended to replace or supplement the salary of the primary investigator.

Sponsor: The AACR Career Development Awards are generously sponsored by the National Cancer Research Foundation and the Susan G. Komen Breast Cancer Foundation.

Eligibility
At the time of application, candidates must be in the first or second year of a full-time, tenure-tracked faculty appointment, at the level of Assistant Professor, in an academic institution anywhere in the world. Candidates must also have completed productive postdoctoral research and demonstrated independent, investigator-initiated research. Employees of a national government and employees of private industry are not eligible. Candidates must be nominated by a member of AACR and must be an AACR member or apply for membership by the time the fellowship application is submitted. AACR Associate Members may not be nominators.

Selection Process
Applications are evaluated by a prestigious, multi-disciplinary committee consisting of AACR Members who are experts in basic, clinical, prevention, and translational research. The application deadline is January 15, 1999.

More Information
The application form and complete guidelines can be requested by contacting AACR at the address below. The materials will soon be available at the AACR’s website, www.aacr.org.

American Association for Cancer Research  
Public Ledger Building, Suite 826  
150 South Independence Mall West  
Philadelphia, PA 19106-3483  
ph: (215) 440-9300; f: (215) 440-9372  
e-mail: horst@aacr.org  
Attn: Jenny Anne Horst-Martz
Notice to Members of the American Association for Cancer Research (AACR)
Officers for 1998–1999
President: Webster K. Cavenee, Ludwig Institute for Cancer Research, La Jolla, CA 92033-0660
President-Elect: Daniel D. Von Hoff, Institute for Drug Development, San Antonio, TX 78245
Treasurer: Bayard D. Clarkson, Memorial Sloan-Kettering Cancer Center, New York, NY 10021
Executive Director: Margaret Foti, AACR, Public Ledger Bldg., Suite 826, Philadelphia, PA 19106-3483

Annual Dues
The annual dues of active members of the AACR are $175, $55 of which may be applied toward a subscription to Cancer Epidemiology, Biomarkers & Prevention. Corresponding members of the Association will be charged an appropriate fee to offset periodicals postage costs. Payment of dues and changes of address of members of the Association should be sent promptly to Margaret Foti, Executive Director, AACR, Public Ledger Bldg., Suite 826, 150 South Independence Mall West, Philadelphia, PA 19106-3483; Telephone: (215) 440-9300; FAX: (215) 440-9313.

Submission of Manuscripts
Cancer Epidemiology, Biomarkers & Prevention publishes original research on cancer causation and prevention in humans, linking three previously unintegrated disciplines: epidemiology, biomarkers, and prevention. Topics include descriptive, analytical, biochemical, and molecular epidemiology; the use of biomarkers to study the neoplastic and preneoplastic processes in humans; chemoprevention and other types of prevention trials; and the role of behavioral factors in cancer etiology and prevention. Manuscripts that address individual subjects in any of the three disciplines are welcome as well as manuscripts with an interdisciplinary approach. All submissions undergo peer review. Papers should be sent to: Cancer Epidemiology, Biomarkers & Prevention, AACR Publications Department, Public Ledger Building, Suite 826, 150 South Independence Mall West, Philadelphia, PA 19106-3483. See Instructions for Authors (page i of this issue) for further information concerning submissions.

Back Issues and Single Copy Sales of the Journal
Copies of back stock of the journal may be ordered from AACR Subscription Office, P. O. Box 11806, Birmingham, AL 35202 (Telephone: (800) 633-4931 or (205) 995-1567; FAX: (205) 995-1588). As long as supplies permit, single copies will be sold by this company at $25.00/copy. Orders outside the U.S. add $3.00/copy to offset postage costs.

Advertisements
Advertisement insertion orders and copy must be received one month prior to the date of issue in which the advertisement is to be published. The journal is mailed by approximately the 7th day of the month of issue. Inquiries about advertising should be directed to: M. J. Mrvica Associates, Inc., 2 West Taunton Avenue, Berlin, NJ 08009 [Telephone: (609) 768-9260; FAX: (609) 753-0064].

Copyright and Permissions
Authors who wish to publish in Cancer Epidemiology, Biomarkers & Prevention must formally transfer copyright to the proprietor of the journal, the AACR, Inc. It is understood by this transfer that the authors relinquish all exclusive rights of copyright ownership, including without limitation rights of reproduction, derivation, distribution, sale, and display of the work, in whole or in part, in any and all forms of media now or hereafter known. Authors who prepared their articles as part of their official duties as employees of the U.S. Federal Government are not required to transfer copyright to the AACR, Inc., since these articles are considered to be in the public domain. In the case of articles supported by federal grants or contracts, copyright transfer to the AACR, Inc., is required. The federal government may retain a nonexclusive license to publish or republish such material.
The Journal will routinely allow authors (or others with the permission of the authors) to include select parts of a copyrighted article in reviews, books, or subsequent papers, upon written request to the AACR Director of Publications. Requests to reproduce an article in its entirety will be considered on an individual basis and permission may be granted contingent upon payment of an appropriate copyright fee. All reproduction requests must include a brief description of intended use and a stamped, self-addressed envelope. Third parties should obtain the approval of the authors before corresponding with the AACR.
Those who wish to photocopy articles should contact the AACR Publications Department [Telephone: (215) 440-9300; FAX: (215) 440-9355].

No responsibility is accepted by the Editors, by the AACR, Inc., by the American Society of Preventive Oncology, or by Cadmus Journal Services for the opinions expressed by contributors or for the content of the advertisements.

Cancer Epidemiology, Biomarkers & Prevention is indexed in Chemical Abstracts, Current Contents/Citations, Index Medicus, MEDLINE, and the BIOSIS Previews® Database. This journal is printed on acid-free paper.

Cancer Epidemiology, Biomarkers & Prevention (ISSN 1055-9965) is published monthly by the American Association for Cancer Research, Inc., Public Ledger Bldg., Suite 826, 150 South Independence Mall West, Philadelphia, PA 19106-3483 for $55 annually for members, $110 for individual nonmembers, and $285 for institutional nonmembers. Periodicals postage paid at Philadelphia, PA and additional mailing offices. POSTMASTER: Send address changes to AACR Subscription Office, P. O. Box 11806, Birmingham, AL 35202. Copyright 1998 by the American Association for Cancer Research, Inc. Printed in the U.S.A.
DARTMOUTH MEDICAL SCHOOL
Norris Cotton Cancer Center
Clinical Cancer Prevention Investigator

Dartmouth Medical School seeks a Clinical Cancer Prevention Investigator to participate in chemoprevention clinical trials and related cancer research. These efforts will be part of an active cancer prevention program, with on-going research involving Phase II/III clinical trials, as well as related laboratory investigation and epidemiological research. Responsibilities will include the conduct and planning of chemoprevention clinical trials and related biologically-oriented epidemiological studies. An appointment at a level appropriate for training and experience will be in the tenure track in the section of Biostatistics and Epidemiology of the Department of Community and Family Medicine. The position will involve affiliation with the Norris Cotton Cancer Center, an NCI-designated comprehensive cancer center. A clinical appointment is also possible, but not required.

Applicants should have a M.D. degree with training in epidemiology, or a Ph.D. in a health-related discipline such as Epidemiology or Pharmacology/Toxicology with a strong history of clinical research. Experience in cancer epidemiology, cancer biology and/or cancer clinical trials is very desirable.

Submit a CV, with publications list and names of three references to: John A. Baron, MD, 7927 Rubin Building, Dartmouth-Hitchcock Medical Center, One Medical Center Drive, Lebanon, NH 03756.

Dartmouth Medical School is an equal opportunity/affirmative action employer. Women with minorities are encouraged to apply. A component of Dartmouth-Hitchcock Medical Center

Cancer Prevention Fellowship

The Wake Forest University School of Medicine is accepting applications for the Cancer Prevention Fellowship Program, a National Cancer Institute-funded postdoctoral fellowship to train individuals from a multiplicity of health science disciplines for academic careers in cancer prevention and control research. The program provides salary support for up to three years of training and tuition for optional graduate work leading to an MS degree in epidemiology.

Eligibility: MD, Ph.D., or other doctoral degree

Citizenship: U.S. Citizen or resident alien of U.S. eligible for citizenship within four years

Request for information or applications:

Electra O. Paskett, Ph.D.
Director, Cancer Prevention Fellowship Program
Wake Forest University School of Medicine
Medical Center Boulevard
Winston-Salem, NC 27157
epaskett@rc.phs.wfubmc.edu

AMERICAN ASSOCIATION FOR CANCER RESEARCH

The American Association for Cancer Research (AACR) is a professional society of over 13,500 scientists and physicians involved in all aspects of basic, clinical, and translational cancer research. Members of the AACR enjoy

- subscriptions to Cancer Research, Cell Growth & Differentiation, Cancer Epidemiology, Biomarkers & Prevention, and Clinical Cancer Research at reduced member rates
- reduced registration rates at the AACR Annual Meeting, Special Conferences, and International Meetings
- Employment Register, Directory of Members, public education activities, and many other benefits

Special programs to provide enhanced career development opportunities for minority scientists include

- Session on Career Development at Annual Meeting
- Mentorship Program
- Travel Awards to Scientific Meetings

American Association for Cancer Research
Public Ledger Building, Suite 826
150 S. Independence Mall West
Philadelphia, PA 19106-3483
Telephone: (215) 440-9300
FAX: (215) 440-9313

Yale University
Assistant Professor of Epidemiology
Cancer Specialization

Yale University School of Medicine, Department of Epidemiology and Public Health, invites applications for a Cancer Epidemiologist at the assistant professor level. Epidemiologists working in any area of cancer will be considered, although candidates with experience in molecular, genetic or other biological aspects of cancer at a population level are particularly encouraged. The selected candidate will be expected to teach, collaborate with other faculty and conduct a program of independent research. Candidates should have a Ph.D. or M.D. degree.

The Yale Comprehensive Cancer Center has core laboratory and population-based case identification resources available. Connecticut is a Surveillance, Epidemiology and End Results (SEER) site, and is the home of one of the oldest cancer registries in the world.

Interested applicants should send, by March 1, 1999, a CV, letter describing research interests and qualifications, and names and addresses of three persons who could provide references to:

Susan T. Mayne, Ph.D.
Cancer Epidemiology Search Committee Chair
Yale University School of Medicine
Department of Epidemiology and Public Health
60 College Street, P.O. Box 208034
New Haven, CT 06520-8034

Yale University is an equal-opportunity, affirmative-action employer, and welcomes applications from qualified women and minority candidates.
EDUCATIONAL SESSIONS AND METHODS WORKSHOPS (SATURDAY AFTERNOON, APRIL 10, 1999)

To Be Announced

OFFICIAL OPENING EVENT (SUNDAY MORNING, APRIL 11, 1999)

Presidential Address (Webster K. Cavenee)
Plenary Session: New Frontiers in Cancer Research
Genetics (Robert A. Weinberg)
Immunology and Vaccines (Lloyd J. Old)
Therapeutics and Translational Research (Judah Folkman)
Hormonal Intervention and Prevention (C. Kent Osborne)
AACC-Pezcoller International Cancer Research Award Lecture
Special Lecture (James D. Watson)

SYMPOSIA

Animal Models for Human Cancer: Recent Developments, New Challenges (Tyler Jacks)
Advances in Chemoprevention (Raymond N. DuBois)
Infectious Agents and Cancer (Nancy E. Mueller)
Ubiquitin and Protein Degradation (Alexander J. Varshavsky)
Genomics, Genetics, and New Approaches to Cancer (Richard D. Klausner)
Transcriptional Regulation and Cancer (Lorraine J. Gudas)
Drug Discovery: From Basic Science to the Clinic (Daniel D. Von Hoff)
Cancer Vaccines (Ronald Levy)
DNA Repair (Richard D. Kolodner)
Telomerases, Centromeres, and Chromosomal Instability (Carol W. Greider)
Basic and Clinical Approaches to Ovarian Cancer (Robert C. Bast, Jr.)
Gene Environment Interactions in Cancer Etiology (Margaret R. Spitz and Kenneth Olden)
Apoptosis (Craig B. Thompson)
Molecular Targeted Therapy (John Mendelsohn)
Basic and Clinical Approaches to Lung Cancer (David Paul Carbone)
Diet and Cancer: Process and Paradox (John D. Potter)
Genetic Instability, DNA Damage, and Checkpoint Regulation (Geoffrey Wahl)
Invasion, Metastasis, and Angiogenesis (Isaiah J. Fidler)
Drug Resistance and Cell Cycle Abnormalities (Joseph R. Bertino)
Hormonally Related Tumors - Basic and Clinical Aspects (Bert W. O'Malley and Marc E. Lippman)
Late Breaking Science (Waan Ki Hong and Webster K. Cavenee)
Topoisomerase 2 in Carcinogenesis and Cancer Treatment (Leroy Fong Liu)
Replication and the Cell Cycle (Jacqueline A. Lees)
Future Directions in Research on Tobacco and Cancer (Virginia L. Ernster)
Advances in Stem Cell Gene Therapy (Cynthia E. Dunbar)

FORUMS

Tamoxifen: Risks and Benefits
Ethical and Legal Issues in Genetic Testing

"MEET-THE-EXPERT" SUNRISE SESSIONS

Drug Resistance (Susan P. C. Cole)
Cancer Screening (Barnett S. Kramer)
Molecular Signaling of CML (Jean Y. J. Wang)
Apoptosis and Chemotherapy (John A. Hickman)
Caspases (Nancy A. Thornberry)
Molecular Cytogenetics (Joe W. Gray)
p53 Gene Therapy-mediated Radio/Chemosensitization (Esther H. Chang)
Clinical and Molecular Genetics of Multiple Endocrine Neoplasia Type 2 (Bruce A. J. Ponder)
Differentiation Therapy (Samuel Waxman)
AIDS-related Malignancies (Ellen G. Feigal)
Tumor Vaccine Therapy (Michael T. Lotze)
Integration of Biological Agents into Radiotherapy (Chang W. Song)
Molecular Detection of Minimal Residual Disease (Theodore F. Zif)
Microsatellite Instability (David Sidransky)
Chemoprevention Trials: Science vs. Art vs. Fantasy (David S. Alberts)
Genetic Imprinting (Andrew P. Feinberg)
Cancer Metastasis: Cellular and Clinical Studies (David Tarin)
Embryonal Stem-cell-based Technology (Randall Johnson)
Replicative Senescence (Judith Campisi)
Drug Design and Development (Randall K. Johnson)
In Vivo Imaging of Gene Expression in Solid Tumors (Ralph Weisleder)

The RB Family and CDKs in the Cell Cycle in Cancer (Antonio Giordano)
Prospects for Biological Agents (Peter J. Houghton)
Disorders in Cell Circuity in Cancer (L. Bernard Weinstein)
bcl2: Its Family and Modification (Timothy J. McDonnell)
Chemoprevention in Respiratory Cancer (Lee W. Wattenberg)
TGF-β and Colon Cancer (Sanford Markowitz)
Inherited Susceptibility to Breast and Ovarian Cancers (Funmi I. Olopade)

VEGF (Harold F. Dowar)
Origins of Melanoma (Margaret A. Tucker)
Biologic of Premalignant Lesions (Walter N. Hittelman)
Genetic Determinants of Prostate Cancer (William B. Isaacs)
DNA Repair: Breaking Cycle-specific Constraints in Combination Therapy (William K. Plunkett)
Antisense Therapies (Stanley T. Crooke)
Topic to be Announced (Saijo Nagahito)
Small Molecule Inhibitors of Protein Kinases That Block Tumor Angiogenesis for the Treatment of Cancer and Metastasis (Jerry McMahon)
Integration of Biological Agents into Chemotherapy (Herbert M. Pinedo)

New Therapeutic Agents (Michael C. Christian)
mvc (Chi Van Dang)
Isolation of Genes Regulated by p53 or Beta-catenin and Their Roles in Human Carcinogenesis (Yusuke Nakamura)
Behavioral Oncology (Barbara K. Rimer)
Mdm2 (Guillermima Lozano)
Molecular Processes in DNA Repair After Irradiation (Gloria C. Li)
Natural Agents and Chemoprevention (Hirotu Fujiki)
Genetics of Wilms Tumor (Michael R. DeBain)

Update on Breast Cancer Treatment (Martin D. Abeloff)

LOCAL ARRANGEMENTS COMMITTEE

Robert F. Ozols, Chairperson

FURTHER INFORMATION:
AACR Office • Public Ledger Building, Suite 826 • 150 S Independence Mall West • Philadelphia, PA 19106-3483 • Telephone 215-440-9300 • FAX 215-440-9313 • E-mail meetings@aacr.org • Website http://www.aacr.org
AMERICAN ASSOCIATION FOR CANCER RESEARCH
Research Grants for Young Cancer Scientists

*New!* Application forms available on-line at http://www.aacr.org

GERTRUDE B. ELION CANCER RESEARCH AWARD
Supported by an Educational Grant from Glaxo Wellcome Oncology

The Gertrude B. Elion Cancer Research Award is a one-year, $30,000 grant for a scientist in the U.S. or Canada engaged in meritorious basic, clinical, or translational research in cancer etiology, diagnosis, treatment, or prevention at the level of Assistant Professor (not yet tenured). The AACR will reimburse the Awardee for travel to the 1999 Annual Meeting in Philadelphia, PA, where Dr. Elion will personally present this Award.

Eligibility/Selection Process
Candidates must have completed postdoctoral studies or clinical fellowships not later than July 1 of the Award year, and ordinarily not more than five years earlier. Tenured faculty in academia, federal government employees, and employees of private industry are not eligible for this award. A Candidate need not be a member of the AACR at the time of application, but must be nominated by a Member of the AACR. Associate Members may not be nominators. Applications are evaluated by a Committee consisting of AACR Members who are experts in basic, clinical, translational, and prevention research. Application deadline: December 15, 1998.

AACR RESEARCH FELLOWSHIPS
For Young Scientists at the Postdoctoral or Clinical Fellow Level
New! Some Two-Year Fellowships

The AACR Research Fellowships in Clinical, Translational, Basic, and Prevention Research foster meritorious cancer research in North, Central, or South America by young scientists currently at the postdoctoral or clinical research fellow level. Sponsored by Amgen, Bristol-Myers Squibb Oncology, Cancer Research Foundation of America, the Sidney Kimmel Foundation for Cancer Research, AACR, and others, the AACR Fellowships provide either one or two years of salary support at the rate of $30,000 per annum. Those awarded two-year grants who receive a junior faculty appointment in the second year may use the funds for non-salary research expenses in connection with the new position.

Eligibility/Selection Process
Candidates must have completed the M.D., Ph.D., or other doctoral degree. Candidates must currently be a postdoctoral or clinical research fellow and must have been a fellow for at least two years but not more than five years prior to the year of the award. Academic faculty, graduate or medical students, medical residents, permanent government employees, employees of private industry, and individuals who will receive fellowships from similar programs during the award year are not eligible. A candidate need not be a member of the AACR at the time of application, but he or she must be nominated by an AACR Member, and non-members must submit an acceptable application for membership with the fellowship application. Associate Members may not be nominators. Applications are evaluated by a Committee consisting of AACR Members who are experts in basic, clinical, translational, and prevention research. Application deadline: January 15, 1999.

For Further Information
AMERICAN ASSOCIATION FOR CANCER RESEARCH
Public Ledger Building, Suite 826
150 South Independence Mall West
Philadelphia, PA 19106-3483
Telephone: (215) 440-9300  FAX: (215) 440-9372  E-mail: horst@aacr.org
**FACULTY LEVEL POSITION, TENURE TRACK OR TENURED**, for top quality research psychologist with training/expertise and grant-getting ability in health psychology-behavioral medicine, focus on oncology, prevention, tobacco control/addiction, behavior changes, and community-based/population studies. Send vita, reprints, and three references to: Dr. Suzanne M. Miller, Director, Psychosocial and Behavioral Medicine Program, Division of Population Science, Fox Chase Cancer Center, 510 Township Line Road, Cheltenham, PA 19012. Equal Opportunity Employer.

**FOX CHASE CANCER CENTER**

**ADVANCED POSTDOCTORAL FELLOW/ASSISTANT FACULTY MEMBER IN PSYCHOSOCIAL ONCOLOGY AND BEHAVIORAL MEDICINE PROGRAM**

Two-year positions available immediately for health psychology/behavioral medicine research, focusing on oncology, coping processes, prevention, and intervention with health risks and disease. Stimulating, interactive research environment with opportunity for promotion and tenure. Training/expertise in health psychology-behavioral medicine or related area (e.g., clinical or social psychology, health education, epidemiology, medical sociology) and grant getting potential essential. Must have demonstrated background in research, with interests in extending the program of work to oncology. Send vita, reprints, and three references to: Dr. Suzanne M. Miller, Director, Psychosocial and Behavioral Medicine Program, Division of Population Science, Fox Chase Cancer Center, 510 Township Line, Cheltenham, PA 19012. Equal Opportunity Employer.

**FOX CHASE CANCER CENTER**

---

**Conference Announcement**

The National Cancer Institute, Office of Cancer Survivorship, is presenting a workshop on "Cancer Survivorship: Challenges and Opportunities for the New Millennium." The conference is a continuation of efforts by the Office of Cancer Survivorship in the Division of Cancer Control and Population Sciences to deal with the issues of importance to survivors and to the professionals who care for them.

**Conference Dates**
March 8-9, 1999

**Location**
Hyatt Regency Hotel
One Bethesda Metro
Bethesda, MD

**Call for Abstracts**
Deadline: December 28, 1998

**Contact**
For conference registration and logistical information, contact Pat Evans, TASCON, Inc., by phone at 301-315-9000, ext. 516, by fax at 301-738-9783, or by e-mail at nci@tascon.com.

For information concerning submission of abstracts or the program, contact Anna Meadows, M.D., or Noreen Aziz, M.D., by phone at 301-496-0598, or by fax at 301-496-8675.

---

**Postdoctoral Fellowship**

**UNC DEPARTMENT OF EPIDEMIOLOGY SCHOOL OF PUBLIC HEALTH LINEBERGER COMPREHENSIVE CANCER CENTER**

**CANCER PREVENTION AND CONTROL**

The UNC Lineberger Comprehensive Cancer Center at the University of North Carolina at Chapel Hill seeks candidates for a two-year postdoctoral fellowship in cancer prevention and control research. Qualified individuals must have completed a Ph.D., M.D. or equivalent degree and must be U.S. citizen or have permanent residential status.

For further information or application, contact:
Michael O'Malley, Ph.D.
UNC Lineberger Comprehensive Cancer Center, CB# 7295
University of North Carolina at Chapel Hill
Chapel Hill, NC 27599-7295
Phone: 919-966-8642 • Fax: 919-966-3015
dolley@ncted.unc.edu

Applicants should include a statement of research interest/proposed work, a curriculum vitae, and three letters of recommendation. Applications are due February 15, 1999. The fellowship will begin in summer 1999.

The UNC Lineberger Comprehensive Cancer Center and the University of North Carolina at Chapel Hill are Equal Opportunity Employers. Women and minorities are strongly encouraged to apply and self-identify on their applications.
## Author Index / Volume 7

### A
- Abbondandolo, A., 147
- Ackman, R. G., 355
- Adami, H.-O., 207, 831
- Adami, J., 831
- Adlercreutz, H., 885
- Ahnen, D., 757
- Ahrens, W., 817
- Ahsan, H. 749, 869
- Aickin, M., 813
- Airdoli, L., 341, 703
- Ajoka, Y., 297
- Akaike, T., 1007
- Akerkar, S., 257
- Akhmedelkorov, A., 885
- Akinyemi, H. 7, 111
- Albanes, D., 533, 1096
- Alberg, A. J., 945
- Alberts, D. S., 813
- Allen, H. A., 419
- Ambinder, R. F., 1117
- Ambrosone, C. B., 37, 181, 1013
- Amos, C. I., 13
- Anderson, K. E., 221
- Andrade, A. F. F., 195
- Andreassen, A., 147
- Apple, S. K., 1027
- Aragonés, N., 621
- Arber, N., 243
- Ardanaz, E., 621
- Armelle, M., 341
- Armstrong, B. K., 857
- Ascherio, A., 283
- Ashbolt, R., 203
- Astrahan, M. A., 43
- Atawodi, S. E., 817
- Audrain, J., 253, 453

### B
- Baba, S., 413
- Babb, J., 315
- Bayoume, D., 351
- Barber, M., 505
- Baron, J., 207
- Baron, J. A., 157, 291, 697
- Barrett, M. J., 1069
- Barrett, R. J., 231
- Bartram, H-P., 1085
- Bartsh, H., 433
- Bean, D., 477
- Beasley, R., 567
- Belinsky, S. A., 1051
- Bell, D. A., 571, 945
- Benatti, P., 639
- Benhamou, S., 19
- Bennett, W. P., 379
- Berglund, G., 803, 809
- Bergomi, M., 851, 853
- Berman, M. L., 231
- Bernstein, D., 489
- Bernstein, L., 365
- Bernino, F., 189
- Bertram, C., 537
- Bigler, J., 1079
- Blackwood, A., 579
- Blair, I. A., 907
- Blaner, W. S., 211

### C
- Belweiss, J. J., 941
- Blizard, L., 203
- Blot, W. J., 97, 749
- Boffetta, P., 817
- Boice, J. D., Jr., 397
- Bolleti, A., 189
- Bondy, M. L., 553
- Bonilla, L. E., 257
- Boone, C. W., 65
- Borciani, N., 851, 853
- Bostick, R. M., 221
- Bouchardy, C., 19
- Bova, G. S., 531
- Bowman, E. D., 453
- Boyd, N. F., 1133
- Boyle, N. R., 253, 453
- Boyle, E. B., 1127
- Braakhuis, B. J. M., 469
- Bracci, P. M., 797
- Braga, C., 329
- Brakenhoff, R. H., 469
- Branch, B., 537
- Brankin, B., 1109
- Breedijk, A., 571
- Breen, N., 951
- Briggs, K., 553
- Briggs, L. A., 141, 981
- Brinton, L. A., 231
- Brockstedt, U., 1019
- Brooks, J. D., 531
- Brotzman, M., 1109
- Brown, M., 379, 1075
- Bruuske-Hohlfied, I., 817
- Bruner, J. M., 553
- Bruzek, D. J., 109
- Bryngelson, C., 803, 809
- Bub, A., 891
- Buckland, J., 1035
- Bu, M., 1043
- Bull, S. A., 1049
- Burt, R. W., 605
- Busch, E., 489
- Bykov, V. J., 199
- Byng, J. W., 1133
- Byrne, C., 523, 1153

### D
- Dalh, D. M., 379
- Dain, B., 207, 291, 783
- Dalil, J. R., 689
- Dallinger, J. W., 571
- Daly, M., 315
- Danels, J. R., 43
- Davico, R., 412
- Davis, R., 227
- Denovellis, F., 1019
- Deardorff, D. C., 791
- Casetta, G., 341
- Casey, P. A., 629
- Castiglione, J. E., 429
- Cerhan, J. R., 221
- Ceri, A., 703
- Chan, D. W., 109
- Chan, K. K., 635
- Chand, D. W., 1069
- Chang, G., 1075
- Channing, K. M., 579
- Chen, B., 127
- Chen, G-C., 559
- Chen, L., 351, 869
- Chen, M-J., 227
- Chen, M-L., 169
- Chen, S-Y., 597
- Chen, T. C., 391
- Cheney, R. T., 419
- Cheng, L., 309, 465
- Childrens, J. M., 347
- Chow, W-H., 97, 661, 749
- Christani, D. C., 169, 823
- Christi, S. U., 1085
- Chung, F-L., 103, 775
- Chung, J. S., 211
- Cibolone, G., 1123
- Cicco, D., 919
- Citron, M., 489
- Clapper, M. L., 597
- Clark, L. C., 847
- Clarke, R., 1109
- Clever, S. L., 211
- Close, D. R., 627
- Cobb, B., 253
- Coda, R., 341
- Coetzee, G. A., 635, 775
- Cohen, A., 477
- Colditz, G. A., 523, 1153
- Comstock, W. G., 945
- Constantinescu, V., 817
- Contois, J., 729
- Coons, T., 1051
- Copper, M., 469
- Corlet, D. K., 605
- Correa, P., 642
- Coxhead, J., 441
- Coyne, C., 951
- Cramer, D. W., 697
- Crosson, K., 1145
- Crowell, J. A., 65
- Crowell, R. E., 1051
- Cullen, M. R., 211
- Cummings, K. M., 967

### E
- Edwards, B. K., 951
- Egan, K. M., 359
- Egner, P. A., 127
- Egorin, M. J., 631
- Ehrig, H., 315
- Eicher, S. A., 309, 465
- Eisenberger, M. A., 631
- Eisenhauer, K., 65
- Elsmith, S., 803, 809
- Ender, C., 127
- Ender, S. M., 365
- English, D. R., 857
- Engstrom, P. F., 315, 597
- Epstein, J. I., 531
- Erdman, J. W., Jr., 1055
- Ernster, V. L., 157, 835
- Estabrook, D., 579
- Evans, A. A., 559

### F
- Fahren, J. W., 1091
- Fairclough, D., 195
- Falk, R. T., 215
- Fanelli, M. A., 791
- Fanelli, R., 703
- Fang, X., 127
- Fante, R., 639
- Farkas, A. J., 459
- Farrow, D. C., 97, 749
- Fazbo, P. G., 1075
- Feldman, R. S., 597
- Fernandez, E., 329
- Fernandez, R. C., 435
- Folsom, A. R., 221
- Fontana, V., 147
- Fornow, G. L., 195
- Forman, M. R., 283
- Fortes, C., 817
- Fournier, D. B., 1055
- Fowler, B. M., 901
- Frame, J. N., 215
- Franceschi, S., 329, 667
- Franke, A. A., 113, 135, 537, 613
- Frankl, H. D., 227, 647
- Fraumeni, J. F., Jr., 97, 749
- Freedman, L. S., 605
- Frenkel, K., 49
- Freundheim, J. L., 181
- Friedman, E., 497
- Friedman, G. D., 25, 1049
- Friesen, M. D., 817
- Frost, F. J., 585
Shirai, Y., 297
Shui, W., 591
Sichel, F., 917, 929
Sideri, M., 237
Sigman, C. C., 65
Simanitis, M., 809
Simon, K., 989
Simonsen, N., 356, 1043
Simpson, J. F., 29
Singh, S., 613
Sinka, R., 523, 1153
Simbaldi, V. J., 631
Skaar, T. C., 1109
Slaade, J., 965
Slater, J. S., 681
Slattery, M. L., 1079
Sleckman, B. G., 1117
Smeets, S., 469
Smith, M., 1145
Snow, G. B., 469
Snoii, Y., 397
Sokoll, L. J., 199
Speizer, F. E., 523, 1153
Spicer, D. V., 43
Spinaci, L., 237
Spitz, M. R., 13, 309, 465, 567, 729
Spolit., N., 237
Srithara, R., 631
Stampfer, M. J., 359, 379, 385, 783, 1001, 1075
Stanford, J. L., 97, 689, 749
Steeg, P. S., 29
Steel, V. E., 65
Steegmeier, S. J., 419
Steinbuch, M., 1127
Stellman, S. D., 489
Stephenson, K. K., 1091
Stermy, N. H., 809
Stidley, C. A., 585
Stone, E. M., 1019
Stovall, E. L., 269
Stovall, M., 397
Strain, A. J., 435
Strain, S., 1043
Streck, R. J., 419, 967
Strickland, P. T., 945
Strom, S. S., 309
Sturgeon, S. R., 231
Su, L.-C. J., 1043
Sugimura, H., 413
Suh, S., 243
Sun, Y., 531

T
Taioli, E., 49
Tajima, K., 261, 413
Takei, K., 1007
Takahashi, H., 473
Takezaki, T., 413
Talalay, P., 1091
Talami, R., 329
Tang, Y.-M., 1013
Tangrea, J., 335, 1069
Tannenbaum, S. R., 635, 1153
Tarone, R. E., 397
Taylor, P. R., 59, 335, 1069
Tekautz, T., 1127
Terbule, P. G., 515
Terrorne, C., 341
Thamm, M., 1043
Thior, I., 1117
Thompson, P. A., 37
Thörn, M., 207
Thormquist, M. D., 405
Tilley, B. C., 119
Titus-Ernstoff, L., 207, 697, 783
Tiwari, R., 321
Tokunaga, M., 449
Tolstoy, L., 359
Tominaga, S., 261
Tomiolo, P., 49, 885
Tosteson, T. D., 515, 757
Travis, L. B., 397
Trentham-Dietz, A., 359
Treptow-van Lishaut, S., 891
Trevisan, M., 189
Trichopoulos, D., 359
Trinkaus, K. M., 585
Tritchler, D. L., 1133
Trzaina, Z., 553
Trock, B., 1109
Tsaih, S.-w., 831
Tse, C.-K., 371
Tugan, S., 413
Tucker, M. A., 215
Turner, P. C., 441
Tutsch, K. D., 907, 989
Twyggs, L. B., 231

U
Ulrich, C., 477
Ungerleider, R., 1145
Ursin, G., 43
Usami, I., 711

V
Vainio, H., 725
Vaittinen, P., 865
Valanis, B., 405
Valerio, F., 3, 147
van Agen, E., 571
van Bennekum, A. M., 211
van den Brandt, P. A., 673
van Leeuwen, B., 813
van Leeuwen, P. E., 397
van Schouwen, F. J., 571, 767
van ‘t Veer, L., 571
van ‘t Veer, P., 356, 1043
van Zandwijk, N., 571
Vargas, P. A., 813
Varricchio, C., 1145
Vaughan, T. L., 97, 749
Velculescu, V. E., 109
Vena, J. E., 181
Vena, S. M., 37
Vergara, A., 621
Verma, A. K., 907, 989
Vernon, S. W., 591
Verselis, S. J., 195
Vigreux, C., 917, 929
Vinceti, M., 851, 853
Vineis, P., 341, 1123
Virtamo, J., 1069
Vivoli, G., 851, 853
Vogel, V. G., 591
Vogelstein, J. H., 483
Vogelstein, B., 109
von Schantz, T., 809

W
Wade, K. L., 1091
Wahid, N., 869
Wakai, K., 413
Waldman, S. A., 505
Wan, Y., 13
Wang, I., 497
Wang-J.-B., 127
Wang-J., 127
Wang-J.-S., 127
Wargovich, M. J., 605
Watanabe, H., 297
Watanabe, K.-i., 711
Weber, D. V., 591
Wei, Q., 399, 465, 553
Weiffenbach, B., 215
Weinstein, M., 531
Weiss, N. S., 689
West, A. B., 97, 749
Weston, A., 147, 545, 941
White, A., 489
White, E., 79, 627
Whittlatch, L. W., 391
Wigbout, G., 571
Wijnhoven, S. W. P., 571
Wilbanks, G. D., 231
Wilkens, L. R., 113, 537
Willet, W. C., 163, 283, 359, 523, 783, 1153
Williams, J. H., Jr., 405
Wingo, P. A., 271
Withersell, H. L., 91
Witte, J. S., 647
Wolff, M., 579, 941
Woods, C., 605
Woosley, J. T., 993
Wrensch, M., 303, 835
Wu, M.-T., 169, 823
Wu, X., 13, 567, 729
Wu, Y., 127
Wynder, E. L., 735
Wypij, D., 169

X
Xu, J., 309
Xu., X., 1101

Y
Yaffe, M. J., 1133
Yang, C. S., 351
Yeh, Y.-F., 823
Yen, T. J., 597
Yokoyama, A., 473
Yokoyama, N., 297
Yokoyama, T., 473
Young, L. N., 309
Yu, L.-Y., 127
Yu, M.-C., 135, 429, 635, 775
Yuan, J.-M., 429
Yuen, J., 207

Z
Zarba, A., 127
Zeleniuch-Jacquotte, A., 885
Zhang, B.-C., 127
Zhang, L., 109
Zhang, P. J., 419
Zhang, Q.-N., 127
Zheng, W., 85, 221
Zhou, W., 109
Zhu, Y.-R., 127
Zou, X.-N., 59
Subject Index / Volume 7

A
Abstracts
American Society of Preventive Oncology annual meeting, 175
N-Acetyltransferase
NAT1
genotype, and breast cancer risk, 371
genotype, and breast DNA adducts, 1019
NAT2
genotype, and breast cancer risk, 371
genotype, and breast DNA adducts, 1019
genotype, and DNA adducts and smoking, short communication, 341
polymorphisms, and cigarette smoking, 1079
polymorphisms, and glioma risk, short communication, 553
polymorphisms, and tobacco smoke exposure, 875
Adenocarcinoma
esophageal
etiology, 265
risk, medication use and, 749
sex hormones and, 913
gastric
risk, medication use and, 749
Adenoma
colorectal
broccoli and GSTM1 null genotype and, 647
hormone replacement therapy and, 227
recurrence, dietary and supplemental calcium and, 291
recurrent, dietary iron and, 556
risk, dietary factors and, 993
risk, rectal mucosal cell proliferation and, 993
Adipose tissue
biomarkers, 1043
fatty acids, European Community Multicenter Study on Antioxidants, Myocardial Infarction, and Breast Cancer, 355
organochlorines, Long Island, New York women, 489
Aflatoxin
biomarkers
oltipraz chemoprevention trial, China, 127
Aflatoxin B1-albumin
serum levels, United Kingdom, 441
African-Americans
smoking risk
dopamine D4 receptors and, 453
Alcohol
consumption
and total estradiol, premenopausal women, 189
Alcohols
esophageal cancer
and ALDH2 genotype, Japanese
alcohols, 473
endoscopic mucosectomy follow-up, Japanese, 473
Aldehyde dehydrogenase-2
genotype
esophageal cancer and, Japanese
alcoholics, 473
Alkaline comet assay
DNA damage and pesticide exposure, 917, 929
Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study
vitamin E, selenium, and prostate cancer, short communication, 335
American Cancer Society
Seventh ACS Award Lecture, 735
American Society of Preventive Oncology
22nd annual meeting abstracts, 175
4-Aminobiphenyl hemoglobin
DNA adducts, smokers, 571
Androgen
serum
and prostate cancer risk, 1069
Androgen receptor
AR gene
GGN microsatellite, and prostate cancer risk, 379
Animal exposures
and childhood brain tumors, 797
Antibodies: see Autoantibodies
Antigen
carcinoembryonic
breast nipple aspirate fluid, 195
class II HLA alleles
and HPV-related cervical neoplasia, 1035
prostate-specific production, female breast, 315
Antioxidants
European Community Multicenter Study on Antioxidants, Myocardial Infarction, and Breast Cancer, 355
workplace environmental tobacco smoke effects, 981
Archival hematological slides
DNA amplification, short communication, 1127
Aromatase inhibitors
cancer chemoprevention, review, 65
Asian population
lung cancer
CyclA1 Ile462Val polymorphisms and, Okinawa, 413
Aspirin
esophageal and gastric cancer risk and, 97
Asthma drugs
esophageal and gastric adenocarcinoma risk and, 749
Atrophic gastritis
endoscopic findings and serum pepsinogen levels, short communication, 261
Autoantibodies
anti-HMDS, cancer risk biomarker, 49
anti-nucleosomin, breast cancer, 1109
Auto workers
diet
psychosocial correlates, 119
Barbiturates
and bladder cancer risk, short communication, 1049
Barrett’s metaplasia
etiology, 265
Basal cell carcinoma
skin
other cancers with, 157
Behavior
cancer-related vitamin supplement users, short communication, 79
Benzo(a)pyrene
DNA adducts
WBCs, police officers, 3
Benzo(a)pyrene-diolepoxide
DNA adducts
and metabolic polymorphisms, 703
Beta-Carotene and Retinol Efficacy Trial
recruitment of smokers, 405
Biological banking
blood specimens
quality control program, 803
normal and tumor tissue, 809
Biomarkers
aflatoxin
oltipraz chemoprevention trial, China, 127
anti-HMDS aAbs, women, 49
breast fine-needle aspiration specimens, quantitative fluorescence image analysis, 1027
cancer
anti-HMDS aAbs, women, 49
mutagen sensitivity, hepatocellular carcinoma, 567
pancreatic cancer
gene expression analysis, 109
plasma vs adipose tissue, 1043
survival
prostate cancer, short communication, 631
tobacco smoke
HPB-Hb adducts, short communication, 817
urinary
dietary isothiocyanates, humans, 103
Biomonitoring
United States Army soldiers, Kuwait, 1991, 545
Bladder cancer
cyclophosphamide-associated p53 mutations, 397
DNA adducts, smoking, and NAT2 and GSTM1 genotypes, short communication, 341
risk
barbiturates and smoking and, short communication, 1049
Bleomycin
chromosomal damage
β-carotene/α-tocopherol effects, 113, 729
Blood
tea polyphenol levels, short communication, 351
white blood cells
DNA adducts, and smoking and NAT2 and GSTM1 genotypes, short communication, 341
DNA adducts, police officers, 3
Brain tumors
childhood
farm and animal exposures and, 797
United States West Coast Childhood Brain Tumor Study results, 797
Breast
cyst fluid
organochlorine compounds, 579
dNA adducts
NAT1, NAT2 and, 1019
female
PSA production, 315
fine-needle aspiration specimens
biomarkers, quantitative fluorescence image analysis, 1027
Breast cancer
adipose fatty acids and, European Community Multicenter Study on Antioxidants, Myocardial Infarction, and Breast Cancer, 355
chemoprevention trial
enrollment status model, 592
coronary heart disease and, 869
CYP17 polymorphisms and, short communication, 945
exercise-diet intervention effects, 477
family history
and risk factors, 359
HDL cholesterol and menopausal status and, 483
hsP27, 791
invasive
retinoid X receptor overexpression, 29
mammography and, managed care organization, 585
nucleophosmin autoantibodies, 1109
risk
breastfeeding and, postmenopausal women, 365
cigarette smoking and, 371
CYP17 genotype and, 941
family history and, 359
mammographic densities and, review, 1133
menstrual factors and, 783
NAT1 and NAT2 and, 371
postmenopausal, environmental organochlorine exposure and, 181
screening interventions, literature review, 951
urinary estrogen metabolites and, 85
Breast disease
benign
plasma and breast cyst fluid organochlorines, 579
Breastfeeding
and breast cancer risk, postmenopausal women, 365
Breast milk
human
exfoliated ductal epithelial cells, 37
Breast nipple aspirate fluid: see Nipple aspirate fluid
Broccoli
and GSTM1 null genotype, colorectal adenoma, 647
Bronchial epithelium
trisomy 20 in, short communication, 1051
C
Calcium
and colorectal cancer, review, 163
dietary
and colorectal adenoma recurrence, 291
and rectal cancer, postmenopausal women, 221
supplemental
and colorectal adenoma recurrence, 291
Calcium channel blockers
esophageal and gastric adenocarcinoma risk and, 749
Cancer: see also specific sites
environmental selenium and, 847
nutritional supplements and, 849
other
with skin cancer, 157
risk markers
trisomy 20, short communication, 1051
triple
DNA repair and mutagen sensitivity, 321
Cancer prevention: see also Chemoprevention
Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study, 335
carotenoid
international evaluation, meeting report, 725
soy and, review, 1055
vitamin E, selenium, and prostate cancer, short communication, 335
Cancer-related behavior
vitamin supplement users, short communication, 79
Cancer survival
long-term
editorial, 269
United States, 271
Cancer survivorship
research issues, meeting report, 1145
Carcinoembryonic antigen
nipple aspirate fluid, 195
β-Carotene
Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study, short communication, 335
Beta-Carotene and Retinol Efficacy Trial, 405
chromosomal damage effects, 113, 729
supplements and lung nutrient levels, 211
Carotenoids
cancer prevention
international evaluation, meeting report, 725
dietary
plasma levels and, 283
plasma and dietary carotenoid intake, 283
paired with cervical tissue, short communication, 347
plasma vs adipose tissue biomarkers, 1043
Catechins
teat
blood and urine levels, short communication, 351
Caucasians
cruciferous vegetable consumers
CYP1A2 and GSTM1 null genotypes and, short communication, 635
melanin estimation by spectrophotometry, 203
smoking risk
dopamine D4 receptors and, 453
Cell proliferation
PolyP Proliferation Trial, 605
rectal mucosal and colorectal adenoma risk, 993
milk and milk product effects, 757
Cell proliferation markers
oral cavity, 597
rectal mucosal proliferation measures, PolyP Proliferation Trial, 605
Cellulosic fibers
inhaled, human lung tissue, 419
Cervical cancer
paired plasma and cervical tissue carotenoid, tocopherol, and retinol levels, short communication, 347
screening interventions, literature review, 951
Cervical dysplasia
risk
plasma micronutrients and, Hawaii, 537
Cervical intraepithelial neoplasia
risk factors, 237
Cervical neoplasia
HPV-related
class I/II HLA alleles and, 1035
Cervical precancer
paired plasma and cervical tissue carotenoid, tocopherol, and retinol levels, short communication, 347
Cervical tissue
carotenoid, tocopherol, and retinol levels paired with plasma, short communication, 347
hypomethylation and folate status, 901
Chemoprevention
aromatase inhibitors, review, 65
combination piroxicam and DFMO, phase I study, 907
oltipraz
trial, China, 127
Chemoprevention trials
breast cancer
enrollment status model, 592
Chemotherapy
pediatric
hprt and TCR mutations, 711
Childbearing
and Hodgkin’s disease risk, short communication, 831
Childhood brain tumors
farm and animal exposures and, 797
United States West Coast Childhood Brain Tumor Study results, 797
Chile
gallbladder carcinoma
p53 mutations, 297
China: see People’s Republic of China
Cholesterol
HDL
and breast cancer, 483
Chromosomal damage
β-carotene/a-tocopherol effects, 113, 729
Chromosome 8
aberrations, acute nonlymphocytic leukemia, 1123
Cigarette filters
glass fiber contamination, 967
Cigarette smoking: see Smoking
Coal tar
dermal exposure
aromatic DNA adducts, 767
Coke-oven workers
CYP1A1 Met polymorphism, short
communication, 823
urinary 1-hydroxypropane levels, short
communication, 169, 823
Colon cancer
confounding factors
dietary isothiocyanates, 645
coronary heart disease and, 869
hormone replacement therapy and, women, 653
malignant
TGF-β1 levels, 497
risk
DMPO and, 989
hormone replacement therapy and, short
communication, 329
NAT2, GSTM1, cigarette smoking, and, 1079
Colon carcinogenesis
high-fat diet, 1007
lipid peroxid radicals, 1007
Colonic mucosa
sodium selenite effects, 1085
Colorectal adenoma
broccoli and GSTM1 null genotype and
647
hormone replacement therapy and, 227
recurrence
dietary and supplemental calcium and, 291
dietary iron and, 556
risk
dietary factors and, 993
rectal mucosal cell proliferation and, 993
Colorectal cancer
calcium and vitamin D and, review, 163
guanosine cyclase C expression, 505
hereditary nonpolyposis
colorectal tumors, short communication, 639
incidence trends, 661
risk
fiber intake and, 667
GSTM1 polymorphisms and, 1001
GSTM1 polymorphisms and, 1001
Colorectal cancers
hereditary nonpolyposis colorectal
carcinoma, short communication, 639
Commentaries
re: J. L. Paul et al., 7: 967–979, 965
re: M. Vincenti et al., 7: 853–856, 847, 849, 851
Coronary heart disease
and cancer, 869
Correa, Pelayo
tribute to, 1
Cruciferous vegetables
consumers
CYP1A2 and GSTM1 null genotypes, short
communication, 635
glucosinolates and isothiocyanates
metabolism and excretion, 1091
urinary ITCs and, 775
Cyclophosphamide-associated bladder
cancer
p53 mutations, 397
Cysts
breast
fluid, organochlorine compounds, 579
Cytochrome P450
CYP17
genotype, and breast cancer risk, 941
polymorphisms, and breast cancer, short
communication, 945
CYP1A1
Ile462Val (exon 7) polymorphisms, and
lung cancer, Asian population, 413
Met polymorphism, coke-oven
workers, short communication, 823
polymorphisms, and BPDE adducts, 703
polymorphisms, and glioma risk, short
communication, 553
CYP1A2
and GSTM1 null genotypes, cruciferous
vegetable consumers, short
communication, 635
CYP2D6
polymorphisms, and lung cancer risk,
215
CYP2D6 (debrisoquine hydroxylase) and
prostate cancer, 1075
CYP2E1
Dr3 polymorphisms, lung cancer, 13
polymorphisms, and esophageal cancer
susceptibility, 1013
Cytological dyskaryosis
mild
cervical intraepithelial neoplasia risk
factors, 237
Cytology smears
quantitative fluorescence image analysis,
China, 59
D
DDE
plasma and breast cyst fluid, 579
Debrisoquine hydroxylase
and prostate cancer, 1075
Dichloro-diphenyl-trichloroethane
plasma and breast cyst fluid, 579
Diet
and colorectal adenoma risk, 993
exercise-diet intervention
effects, breast cancer patients, 477
high-fat, colon carcinogenesis, 1007
Malmö Diet and Cancer Study
normal and tumor tissue biological
banking, 809
quality control program, 803
psychosocial correlates, male auto
workers, 119
Dietary calcium
and colorectal adenoma recurrence, 291
Dietary carotenoids
plasma levels and, 283
Dietary heterocyclic amines
predictors, 523, 1153
Dietary iron
and colorectal adenoma recurrence,
556
Dietary isothiocyanates
confounding factors, colon cancer, 645
urinary biomarker, humans, 103
urinary ITCs and, 775
Dietary soy
urinary isoflavone excretion and,
multiracial women, 613
urinary isoflavonoids and, Chinese, 135
α-Difluoromethylornithine
colon cancer risk and, 989
combined with piroxicam, phase I
chemoprevention study, 907
1,25-Dihydroxyvitamin D3
synthesis by prostate cells, human, 391
Dipyrimidine dimers
induction by solar-simulating UV
radiation, 199
DNA
genomic
mouthwash method for obtaining, short
communication, 719
DNA adducts
aflatoxin-albumin
biomarkers, olitpizex chemoprevention
trial, 127
4-aminobiphenyl hemoglobin, smokers,
571
aromatic
smokers, 571
WBCs, police officers, 3
benzo(a)pyrene-diolepoxide
and metabolic polymorphisms, 703
breast
NAT1 and NAT2 and, 1019
etheno
liver, Wilson’s disease/primary
hemochromatosis, 435
4-hydroxy-1-(3-pyridyl)-1-butane
hemoglobin
tobacco smoke biomarkers, short
communication, 817
poly cyclic aromatic hydrocarbon
dermal coal tar exposure, 767
white blood cell
and smoking and NAT2 and GSTM1
genotypes, short communication, 341
DNA amplification
archival slides, short communication, 1127
DNA damage
and pesticide exposure, 917
reduction by vegetable consumption,
mechanisms, 891
specific pesticides and, farmers, 929
DNA repair
capacity, head and neck cancer, 465
triple cancers, 321
Dopamine receptors
D4
and smoking risk, African-Americans
and Caucasians, 453
Drugs: see also specific drugs
nonsteroidal anti-inflammatory
esophageal and gastric cancer risk and,
97
Ductal carcinoma in situ
recurrence risk, 689
retinoid X receptor overexpression, 29
Ductal epithelial cells
exfoliated, human breast milk, 37
Dysplasia
cervical
risk, plasma micronutrients and, 537
Dysplastic leukoplakia
oral
cell proliferation markers, 597
E
Eclipse
glass fiber contamination, 967
Editorials
colon cancer
dietary isothiocyanates as confounding
factors, 645
environmental selenium and cancer, 847
long-term survivors of cancer, 269
manuscript review process, 89
nutritional supplements and cancer risk, 849
tobacco product design, 965
tribute to Pelyo Correa, founding editor, 1
Endometrioid uterine carcinoma
histopathologic features, 231
Endoscopic mucosectomy
esophageal cancer
Follow-up, Japanese alcoholics, 473
Endoscopy
atrophic gastritis indicator
and serum pepsinogen levels, short
communication, 261
Environmental organochlorine
diabetes and postmenopausal breast cancer risk, 181
Environmental selenium
cancer, 847
melanoma incidence, selenium-exposed
cohort, 851, 853
Environmental tobacco smoke
hospital workers
urinary N-NAL-11uGlc, short
communication, 257
workplace
antioxidant effects, 981
and oxidative stress, 142, 981
Epithelial cells
ductal
exfoliated, human breast milk, 37
oral
proliferation markers, 597
Epithelial ovarian cancer
risk
psychotropic medication use and, 697
Epoxide hydrolase
microsomal mEH gene polymorphisms
and BPDE adducts, 703
Epstein-Barr virus
gastric cancer, short communication, 449
Hodgkin's disease, 1117
Esophageal adenocarcinoma
etiology, 265
risk
medication use and, 749
sex hormones and, 913
Esophageal cancer
and ALDH2 genotype, Japanese alcoholics, 473
diagnostic mucosectomy
Follow-up, Japanese alcoholics, 473
QFIA of cytology smears and, China, 59
risk
NSAIDs and, 97
susceptibility
GSTM1, GSTP1, and GSTM1 and
CYP2E1 polymorphisms and, 1013
Estradiol
total
alcohol consumption and, premenopausal women, 189
Estrogen metabolism
soy isoflavone effects, premenopausal
women, 1101
serum
and prostate cancer risk, 1069
urinary metabolites
and breast cancer, 85
Etheno-DNA adducts
liver, Wilson's disease, primary
hemochromatosis, 435
European Community Multicenter Study
on Antioxidants, Myocardial
Infarction, and Breast Cancer
adipose tissue fatty acids, 355
Exercise-diet intervention
effects, breast cancer patients, 477
Exfoliated cells
ductal epithelial
human breast milk, 37
oral
mRNA, 469
F
Familial risks
in situ cancers, 865
Family-Cancer Database
in situ cancers
familial risks, 865
Family history
and breast cancer risk factors, 359
Farmers
DNA damage
pesticide exposure and, 917
specific pesticide and, 929
Farm exposures
and childhood brain tumors, 797
Fat
high-fat diet, colon carcinogenesis, 1007
Fatty acids
adipose, European Community Multicenter
Study on Antioxidants, Myocardial
Infarction, and Breast Cancer, 355
Female breast: see also Breast
PSA production, 315
Fiber
and colorectal cancer risk, 667
glass
smoking exposure, 967
inhaled cellularulotic and plastic, human lung
malignant
Wheat Bran Fiber Trial
design and baseline characteristics, short
communication, 813
Fine-needle aspiration
breast specimens
biomarkers, quantitative fluorescence
image analysis, 1027
Fluorescence image analysis
quantitative
cytology smears, China, 59
Folates
status
hypomethylation and, cervical tissue, 901
Fructose
consumption
and prostate cancer risk, Netherlands, 673
F
Galbladder carcinoma
p53 mutations, Japan and Chile, 297
Gastric adenocarcinoma
risk
medication use and, 749
Gastric cancer
Epstein-Barr virus, short communication, 449
Gastric cardia cancer
QFIA of cytology smears and, China, 59
Gastritis
atrophic
esophageal findings and serum
pepsinogen levels, short
communication, 261
Gastroesophageal reflux
medications that promote
esophageal and gastric adenocarcinoma
risk and, 749
Genes: see specific genes
Genetic metal storage disorders
etheno-DNA adducts, 435
Genomic DNA
mouthwash method for obtaining, short
communication, 719
Genotypes
ALDH2
esophageal cancer and, Japanese
alcoholics, 473
CYP17
and breast cancer risk, 941
GSTM1
DNA adducts and smoking and, short
communication, 341
larynx cancer risk and, 19
GSTM1 null
broccoli and, colorectal adenoma, 647
CYP1A2 activity and, cruciferous
vegetable consumers, short
communication, 635
GSTT1
larynx cancer risk and, 19
NAT1
and breast cancer risk, 371
and breast DNA adducts, 1019
NAT2
and breast cancer risk, 371
and breast DNA adducts, 1019
DNA adducts and smoking and, short
communication, 341
Geographic variation
hepatitis B carrier viral load, 559
Glass fiber
cigarette filter contamination, 967
Glioma
malignant
p53 mutations, 303
risk
gene polymorphisms and, short
communication, 553
Glucosinolase
cruciferous vegetable
metabolism and excretion, 1091
Glutathione S-transferase
status
urinary ITCs and, 775
Glutathione S-transferase \pi
GSTP1
CG methylation, prostatic intraepithelial
neoplasia, 531
polymorphisms, and esophageal cancer
susceptibility, 1013
Glutathione S-transferase \mu
GSTM1
genotype, DNA adducts and smoking
and, short communication, 341
genotype, larynx cancer risk and, 19
quantitative fluorescence image analysis, 59

Lipid peroxidation
etheno-DNA adducts
liver, Wilson's disease/primary
hemochromatosis, 435

Lipid peroxyl radicals
colon carcinogenesis, 1007

Liver
etheno-DNA adducts, Wilson's disease/primary
hemochromatosis, 435

Long Island, New York
women
adipose tissue and serum
organochlorines, 489

Lung
β-carotene and vitamin A levels, 211
inhaled fibers, human, 419

Lung cancer
CYP1A1 Ile462Val polymorphisms and,
Asian population, 413
CYP2E1 Dral polymorphisms, minority
populations, 13
prevention
Seventh ACS Award Lecture, 735
trial recruitment strategies, Beta-
Carotene and Retinol Efficacy Trial, 405
risk
CYP2D6 polymorphisms and, 215
risk markers
trisomy 20, short communication, 1051

Lymphoma: see Non-Hodgkin's lymphoma

M

Malignancy
glioma
p53 mutations, 303

Malmö Diet and Cancer Study
normal and tumor tissue biological
banking, 809
quality control program, 803

Mammography
and breast cancer, managed care
organization members, 585
compliance
measuring, 681
density
and breast cancer risk, review, 1133
measuring changes, 43, 174

Managed care organization members
female
mammography and breast cancer, 585

Manuscript review
process, editorial, 89

Medications: see also specific medications
esophageal and gastric adenocarcinoma
risk and, 749
psychotropic
and ovarian cancer risk, 697

Meeting reports
cancer survivorship research issues, 1145
international evaluation of carotenoid
cancer prevention, 725

Melanin
estimation by spectrophotometry,
Caucasians, 203

Melanoma
incidence, selenium-exposed cohort, 851,
853
Men
auto workers
diet, psychosocial correlates, 119
Menopause
HDL cholesterol and breast cancer and,
483
Menstrual factors
breast cancer risk and, 783
Messenger RNA
exfoliated oral cell, 469

Metal storage disorders
 genetic
etheno-DNA adducts, 435

Metaplasia
Barrett's
etiology, 265

Metastasis
colon cancer
tGF-B1 levels, 497

4-(Methylnitrosamino)-1-(3-pyridyl)-1-
butanone
urinary metabolites
environmentally exposed hospital
workers, short communication, 257

(4-Methylthiosemicarbazono)-1-(3-pyridyl)-1-
butoxy-1-[β-O-ß-D-glucuronosyl]-4-
phloroglucinol
colorectal cancer
CYP2E1 Dral polymorphisms, 13

Mouthwash method
for obtaining DNA, short communication,
719

Mucosa
colonic
sodium selenite effects, 1085
rectal
cell proliferation, and colorectal
denoma risk, 993
cellular proliferation, milk and milk product
effects, 757
cellular proliferation measures, Polyp
Proliferation Trial, 605

Mucoscopy
endoscopic
esophageal cancer, follow-up, Japanese
alcohols, 473

Multietnic women
urinary isoflavone excretion, 613

Mutagen sensitivity
hepatocellular carcinoma, 567
triple cancers, 321

Mutations
hprr, pediatric cancer chemotherapy, 711
K-ras

pancreatic lesions, 515
p53
cyclophosphamide-associated bladder
cancer, 397
gallbladder carcinoma, Japan and Chile, 297
malignant gliomas, 303

TCR, pediatric cancer chemotherapy, 711

MutL homologue
human hMLH1 gene
expression, head and neck cancer, 309,
841

MutS homologue
human hMSH6 gene
expression, head and neck cancer, 309,
841

N

National Cancer Institute Office of Cancer
Survivorship
meeting report, 1145

Navarre, Spain
non-Hodgkin's lymphoma incidence, 621

Neoplasm
cervical
HPV-related, class I/II HLA alleles and,
1035
cervical intraepithelial
risk factors, 237
prostatic intraepithelial
GSTM1 CG methylation, 531

Netherlands
prostate cancer risk
vegetable and fruit consumption and,
673

Nevi
atypical
factors, population-based study, 207

News
grant awards, 731

New York
women
adipose tissue and serum
organochlorines, 489

Nipple aspirate fluid
carcinomembrionic antigen, 195
Chinese women, short communication, 835
prostate-specific antigen
progesterone and, 315

Non-Hodgkin's lymphoma
incidence, Spain, 621
risk
smoking and, 25

Nonsteroidal anti-inflammatory drugs
esophageal and gastric cancer risk and, 97

Nucleophosphin
autoantibodies, breast cancer, 1109

Nutritional supplements
and cancer risk, 849

O

Occupational exposures
chromosome 8 aberrations and, acute
nonlymphocytic leukemia, 1123

Office of Cancer Survivorship
meeting report, 1145

Okinawa
Asian population
CyplA1 Ile462Val polymorphisms and
lung cancer, 413
| **Oltipraz** | chemoprevention trial, China, 127 |
| **Oral cells** | exfoliated mRNA, 469 |
| **Oral precancer** | proliferative markers, 597 |
| **Organochlorines** | adipose tissue and serum, Long Island, New York women, 489 environmental exposure and postmenopausal breast cancer risk, 181 plasma and breast cyst fluid, 579 **Ovarian cancer** | risk **Oxidative stress** | workplace environmental tobacco smoke and, 142, 981 |
| **P** | p53 mutations cyclophosphamide-associated bladder cancer, 397 gallbladder carcinoma, Japan and Chile, 297 malignant gliomas, 303 **Pancreatic cancer** | markers gene expression analysis, 109 **Pancreatic lesions** | K-ras mutations, 515 **Pediatric brain tumors:** see Childhood brain tumors **Pediatric chemotherapy** | **hprt and TCR mutations, 711** |
| **People’s Republic of China** | colorectal cancer incidence trends, 661 gastric cardia cancer cytology smears quantitative fluorescence image analysis, 59 olitpizam chemoprevention trial, 127 prostate cancer incidence, 83 Singapore Chinese urinary isoflavonoids and dietary soy intake, 135 women nipple aspirate fluid, short communication, 835 **Pepsinogen** | serum levels atrophic gastritis, endoscopic findings and, short communication, 261 **Pesticides** | and DNA damage, farmers, 929 exposure DNA damage and, 917 organochlorine adipose tissue and serum, Long Island, New York women, 489 **Physicians** | prostate cancer risk vitamin D and, United States, 385 **Phytoestrogens** | isoflavonoid serum measurements, reliability, 885 metabolism soy isoflavone effects, premenopausal women, 1101 **Piroxicam** | combined with DFMO, phase I chemoprevention study, 907 **Plasma** | biomarkers, 1043 carotenoid levels and dietary carotenoid intake, 283 paired with cervical tissue, short communication, 347 micronutrients and cervical dysplasia risk, Hawaii, 537 organochlorine compounds, 579 retinol levels paired with cervical tissue levels, short communication, 347 tocopherol levels paired with cervical tissue levels, short communication, 347 **Plastic fibers** | inhaled, human lung tissue, 419 **Police officers** | WBC DNA adducts, 3 **Polychlorinated biphenyl** | plasma and breast cyst fluid, 579 **Polycyclic aromatic hydrocarbon** | DNA adducts dermal coal tar exposure, 767 smokers, 571 WBCs, police officers, 3 occupational exposure chromosome 8 aberrations and, acute nonlymphocytic leukemia, 1123 **Polyphenol** tea blood and urine levels, short communication, 351 **Polyp Proliferation Trial** | rectal mucosal proliferation measures, 605 **Precancer** | cervical paired plasma and cervical tissue carotenoid, tocopherol, and retinol levels, short communication, 347 oral proliferative markers, 597 **Progesterone** and nipple aspirate PSA, 315 **Proliferation** | Polyp Proliferation Trial, 605 rectal mucosal proliferation measures, 605 **Polyp Proliferation markers** | oral precancer, 597 rectal mucosal proliferation measures, Polyp Proliferation Trial, 605 **Prostate 1,25-(OH)2D3 synthesis, human, 391** **Prostate cancer** | baseline vitamin E and selenium and, short communication, 335 coronary heart disease and, 869 debrisoquine hydroxylase (CYP2D6) and, 1075 incidence, China, 83 risk AR gene GGN microsatellite and, 379 serum androgens and estrogens and, 1069 vegetable and fruit consumption and, Netherlands, 673 vitamin D and, United States physicians, 385 screening Washington State, short communication, 627 survival biomarkers, short communication, 631 **Prostatic specific antigen** production, female breast, 315 **Prostatic intraepithelial neoplasia** | GSTP1/ CG methylation, 531 **Psychotropic medications** and ovarian cancer risk, 697 **Q** | Quality control program biologically banked blood specimens, 803 **Quantitative fluorescence image analysis** | breast fine-needle aspiration specimen biomarkers, 1027 cytology smears, China, 59 **R** | Receptors: see specific receptors **Rectal cancer** | calcium and vitamin intake and, postmenopausal women, 221 risk hormone replacement therapy and, short communication, 329 **Rectal mucosa** | cell proliferation and colorectal adenoma risk, 993 measures, Polyp Proliferation Trial, 605 milk and milk product effects, 757 **Renal cell carcinoma** | tobacco use and, 429 **Retinoid X receptor** overexpression, ductal carcinoma in situ, 29 **Retinol** | paired plasma and cervical tissue, short communication, 347 **S** | Selenium and prostate cancer, short communication, 335 environmental and cancer, 847 melanoma incidence, selenium-exposed cohort, 851, 853 Serotonin transporter gene role in cigarette smoking, short communication, 253 **Serum** | Альбумин levels, United Kingdom, 441 androgens and prostate cancer risk, 1069 estrogens and prostate cancer risk, 1069 isoflavonoid phytoestrogen levels measurements, reliability, 885 lignan levels measurements, reliability, 885 organochlorines, Long Island, New York women, 489 pepsinogen levels |
Vitamin supplement users
cancer-related behavior, short communication, 79

W
Washington State
prostate cancer screening, short communication, 627

Wheat Bran Fiber Trial
design and baseline characteristics, short communication, 813

White blood cells
DNA adducts
police officers, 3
and smoking and NAT2 and GSTM1 genotypes, short communication, 341

Wilson’s disease
etheno-DNA adducts, 435

Women
adipose tissue and serum organochlorines,
Long Island, New York, 489
cancer risk biomarkers
anti-HMдU aAbs, 49
Chinese
nipple aspirate fluid, short communication, 835
colon cancer
hormone replacement therapy and, 653
managed care organization members
mammography and breast cancer, 585
multiethnic
urinary isoflavone excretion, 613
postmenopausal

breastfeeding and breast cancer risk, 365
rectal cancer, calcium and vitamin intake and, 221
premenopausal
alcohol consumption and total estradiol, 189
estrogen and phytoestrogen metabolism,
soy isoflavone effects, 1101

Workplace
environmental tobacco smoke
antioxidant effects, 981
and oxidative stress, 142, 981

Z
Zaragoza, Spain
non-Hodgkin’s lymphoma incidence, 621